PMI bids to gain first ever FDA modified-risk approval for iQOS

6th December 2016 | Regulatory briefing |

Philip Morris International (PMI) this week submitted its iQOS technology for approval as a reduced-risk product by the U.S. Food and Drug Administration (FDA), a strategy which if successful would provide a tremendous boost to the credibility of heat-not-burn and perhaps pave the way for PMI’s partner Altria to dominate that market in the United States.

Innovation and intellectual property rights for the e-cig industry

1st March 2016 | Regulatory briefing |

    Executive summary   The growth of e-cigarette popularity has been accompanied by a growing number of patent applications and disputes. The World Intellectual Property Office (WIPO) registered more than 1000 patents with the word “electronic cigarette” in the title. Patents aren’t efficient on their own – they should be combined with other IP […]